Drug intelligence / Profile preview

antisense oligonucleotide + porous silicon nanoparticles

Development stage: Preclinical
Lead developer: Queensland University of Technology
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

A research-stage multifunctional nanocarrier platform designed for the treatment of glioblastoma (GBM). It consists of porous silicon nanoparticles (pSiNPs) loaded with antisense oligonucleotides (AON) specifically targeting the downregulated in renal cell carcinoma (DRR) gene. The DRR protein is a key driver of GBM invasion and metastasis. The pSiNPs serve as a biocompatible, biodegradable delivery vehicle capable of crossing the blood-brain barrier (BBB) via Class A scavenger receptors (SR-A). Once internalized, the AON is released to knock down DRR expression, thereby inhibiting tumor cell migration. The platform can also be co-loaded with chemotherapeutic agents like temozolomide (TMZ) to enhance cytotoxicity against GBM cells.

Other names: AON-modified pSiNPsDRR-targeting AON@pSiNPs

Targets

MSR1 (Amyloid beta precursor protein binding family B member 3)FAM107A

Beyond the preview

Go deeper on antisense oligonucleotide + porous silicon nanoparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on antisense oligonucleotide + porous silicon nanoparticles.

Explore the full profile